Aspira Women’s Health (NASDAQ:AWH) Lowered to “Sell” at StockNews.com

Aspira Women’s Health (NASDAQ:AWH) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday.

Separately, Alliance Global Partners reduced their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

Aspira Women’s Health stock remained flat at $0.96 during midday trading on Friday. 59,521 shares of the company’s stock were exchanged, compared to its average volume of 68,951. The stock has a fifty day moving average price of $1.19 and a two-hundred day moving average price of $2.36. The firm has a market cap of $11.98 million, a price-to-earnings ratio of -0.66 and a beta of 1.48. Aspira Women’s Health has a 52-week low of $0.86 and a 52-week high of $6.59.

Aspira Women’s Health (NASDAQ:AWH) last posted its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The firm had revenue of $2.42 million for the quarter, compared to analyst estimates of $2.60 million. During the same period in the previous year, the firm earned ($0.28) earnings per share. On average, research analysts expect that Aspira Women’s Health will post -1.26 EPS for the current year.

Institutional Trading of Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent quarter. 12.19% of the stock is currently owned by institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.